IRF4 is altered in 9.87% of diffuse large B-cell lymphoma patients [3].

IRF4 is an inclusion criterion in 13 clinical trials for diffuse large B-cell lymphoma, of which 12 are open and 1 is closed. Of the trials that contain IRF4 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [4].

IRF4 is an inclusion criterion in 6 clinical trials for transformed non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain IRF4 status and transformed non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

IRF4 is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma activated B-cell type, of which 4 are open and 1 is closed. Of the trials that contain IRF4 status and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 1 is phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

IRF4 is altered in 9.88% of diffuse large B-cell lymphoma, not otherwise specified patients [3].

IRF4 is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 4 are open and 0 are closed. Of the trials that contain IRF4 status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [4].

IRF4 is an inclusion criterion in 4 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain IRF4 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is no phase specified (1 open) [4].

IRF4 is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 4 are open and 0 are closed. Of the trials that contain IRF4 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 4 clinical trials for triple-hit lymphoma, of which 4 are open and 0 are closed. Of the trials that contain IRF4 status and triple-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 2 (1 open) [4].

IRF4 is altered in 2.47% of mantle cell lymphoma patients [3].

IRF4 is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain IRF4 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 3 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain IRF4 status and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [4].

IRF4 is an inclusion criterion in 3 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 3 are open and 0 are closed. Of the trials that contain IRF4 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [4].

IRF4 is an inclusion criterion in 3 clinical trials for intravascular large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain IRF4 status and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

IRF4 is an inclusion criterion in 3 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 3 are open and 0 are closed. Of the trials that contain IRF4 status and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

IRF4 is altered in 23.08% of mediastinal large B-cell lymphoma patients [3].

IRF4 is an inclusion criterion in 2 clinical trials for mediastinal large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IRF4 is altered in 23.08% of primary mediastinal B-cell lymphoma patients [3].

IRF4 is an inclusion criterion in 2 clinical trials for primary mediastinal B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and primary mediastinal B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) [4].

IRF4 is altered in 1.18% of follicular lymphoma patients [3].

IRF4 is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IRF4 status and follicular lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

IRF4 is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 2 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open) and 1 is no phase specified (1 open) [4].

IRF4 is an inclusion criterion in 2 clinical trials for lymphomatoid granulomatosis, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 2 clinical trials for primary central nervous system lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and primary central nervous system lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

IRF4 is an inclusion criterion in 2 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IRF4 status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IRF4 is altered in 3.7% of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue patients [3].

IRF4 is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is altered in 1.64% of marginal zone lymphoma patients [3].

IRF4 is an inclusion criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRF4 status and marginal zone lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

IRF4 is altered in 5.1% of B-cell non-hodgkin lymphoma patients [3].

IRF4 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for ALK-positive large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and ALK-positive large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for breast lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and breast lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains IRF4 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for grade 3b follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and grade 3b follicular lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRF4 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for testicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and testicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IRF4 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 0 are open and 1 is closed. Of the trial that contains IRF4 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].